Articles related to MENTAL HEALTH

An 8-week observational study of young adults with acne found significant improvements in both acne severity and dermatology-related quality of life. Improvements in clinical grading did not correlate with patient-reported quality-of-life gains, highlighting the multidimensional impact of acne.

A Phase 2 trial of luvesilocin reported rapid reductions in postpartum depression symptoms, with most treated participants reaching remission within seven days. The investigational psychedelic has received FDA Breakthrough Therapy designation, but Phase 3 confirmation remains pending.

A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.

Creatine supplementation showed mixed effects on depressive symptoms across five randomized trials involving patients with mood disorders. The early findings suggest potential adjunctive benefit in some populations but do not establish a consistent treatment effect.

Short-term benzodiazepine use after mass trauma was not associated with increased 12-month PTSD risk in a large retrospective cohort. Persistent use showed a different pattern, and the observational findings did not establish causality.

Celebrity disclosures about using beta blockers for performance anxiety are prompting patient questions in primary care, reviving a decades-old off-label use with a comparatively lower risk profile than benzodiazepines.